Literature DB >> 22222766

A superoxide-mediated mitogen-activated protein kinase phosphatase-1 degradation and c-Jun NH(2)-terminal kinase activation pathway for luteolin-induced lung cancer cytotoxicity.

Lang Bai1, Xiuling Xu, Qiong Wang, Shanling Xu, Wei Ju, Xia Wang, Wenshu Chen, Weiyang He, Hong Tang, Yong Lin.   

Abstract

Although luteolin is identified as a potential cancer therapeutic and preventive agent because of its potent cancer cell-killing activity, the molecular mechanisms by which its cancer cell cytotoxicity is achieved have not been well elucidated. In this report, luteolin-induced cellular signaling was systematically investigated, and a novel pathway for luteolin's lung cancer killing was identified. The results show that induction of superoxide is an early and crucial step for luteolin-induced apoptotic and nonapoptotic death in lung cancer cells. The c-Jun N-terminal kinase (JNK) was potently activated after superoxide accumulation. Suppression of superoxide completely blocked luteolin-induced JNK activation, which was well correlated to alleviation of luteolin's cytotoxicity. Although luteolin slightly stimulated the JNK-activating kinase mitogen-activated protein kinase kinase 7, the latter was not dependent on superoxide. We further found that luteolin triggers a superoxide-dependent rapid degradation of the JNK-inactivating phosphatase mitogen-activated protein kinase phosphatase-1 (MKP-1). Introduction of a degradation-resistant MKP-1 mutant effectively attenuated luteolin-induced JNK activation and cytotoxicity, suggesting that inhibition of the JNK suppressor MKP-1 plays a major role in luteolin-induced lung cancer cell death. Taken together, our results unveil a novel pathway consisting of superoxide, MKP-1, and JNK for luteolin's cytotoxicity in lung cancer cells, and manipulation of this pathway could be a useful approach for applying luteolin for lung cancer prevention and therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22222766      PMCID: PMC3310416          DOI: 10.1124/mol.111.076653

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  35 in total

1.  Effects of luteolin on the inhibition of proliferation and induction of apoptosis in human myeloid leukaemia cells.

Authors:  W G Ko; T H Kang; S J Lee; Y C Kim; B H Lee
Journal:  Phytother Res       Date:  2002-05       Impact factor: 5.878

Review 2.  The true face of JNK activation in apoptosis.

Authors:  Anning Lin; Benjamin Dibling
Journal:  Aging Cell       Date:  2002-12       Impact factor: 9.304

3.  Intake of flavonoids and lung cancer.

Authors:  L Le Marchand; S P Murphy; J H Hankin; L R Wilkens; L N Kolonel
Journal:  J Natl Cancer Inst       Date:  2000-01-19       Impact factor: 13.506

4.  Flavonol and flavone intake and the risk of cancer in male smokers (Finland).

Authors:  T Hirvonen; J Virtamo; P Korhonen; D Albanes; P Pietinen
Journal:  Cancer Causes Control       Date:  2001-11       Impact factor: 2.506

5.  Inhibitory effect of Perilla leaf extract and luteolin on mouse skin tumor promotion.

Authors:  Hiroshi Ueda; Chikako Yamazaki; Masatoshi Yamazaki
Journal:  Biol Pharm Bull       Date:  2003-04       Impact factor: 2.233

6.  Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation.

Authors:  J M Brondello; J Pouysségur; F R McKenzie
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

7.  Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells.

Authors:  P L Puri; Z Wu; P Zhang; L D Wood; K S Bhakta; J Han; J R Feramisco; M Karin; J Y Wang
Journal:  Genes Dev       Date:  2000-03-01       Impact factor: 11.361

Review 8.  Dietary agents in cancer prevention: flavonoids and isoflavonoids.

Authors:  D F Birt; S Hendrich; W Wang
Journal:  Pharmacol Ther       Date:  2001 May-Jun       Impact factor: 12.310

9.  Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.

Authors:  Lung-Ta Lee; Ying-Tang Huang; Jiuan-Jiuan Hwang; Ping-Ping H Lee; Ferng-Chun Ke; Madhavan P Nair; Chithan Kanadaswam; Ming-Ting Lee
Journal:  Anticancer Res       Date:  2002 May-Jun       Impact factor: 2.480

10.  Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells.

Authors:  Quan Liao; Junchao Guo; Jörg Kleeff; Arthur Zimmermann; Markus W Büchler; Murray Korc; Helmut Friess
Journal:  Gastroenterology       Date:  2003-06       Impact factor: 22.682

View more
  13 in total

1.  Hepatitis B virus X protein promotes hepatocellular carcinoma invasion and metastasis via upregulating thioredoxin interacting protein.

Authors:  Zhiliang He; Youjia Yu; Yunhong Nong; Lingyao Du; Cong Liu; Yong Cao; Lang Bai; Hong Tang
Journal:  Oncol Lett       Date:  2017-06-01       Impact factor: 2.967

2.  Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation.

Authors:  Xu-Qin Feng; Li-Wen Rong; Rui-Xue Wang; Xue-Lian Zheng; Lei Zhang; Lin Zhang; Yong Lin; Xia Wang; Zhi-Ping Li
Journal:  Oncol Lett       Date:  2018-05-04       Impact factor: 2.967

Review 3.  Diversity and specificity of the mitogen-activated protein kinase phosphatase-1 functions.

Authors:  Ahmed Lawan; Hao Shi; Florian Gatzke; Anton M Bennett
Journal:  Cell Mol Life Sci       Date:  2012-06-14       Impact factor: 9.261

4.  Receptor-interacting protein 1 increases chemoresistance by maintaining inhibitor of apoptosis protein levels and reducing reactive oxygen species through a microRNA-146a-mediated catalase pathway.

Authors:  Qiong Wang; Wenshu Chen; Lang Bai; Wenjie Chen; Mabel T Padilla; Amy S Lin; Shaoqing Shi; Xia Wang; Yong Lin
Journal:  J Biol Chem       Date:  2014-01-14       Impact factor: 5.157

5.  A signaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance.

Authors:  Xiuling Xu; Alexandria Wells; Mabel T Padilla; Kosuke Kato; Kwang Chul Kim; Yong Lin
Journal:  Carcinogenesis       Date:  2014-08-01       Impact factor: 4.944

6.  RIP1 potentiates BPDE-induced transformation in human bronchial epithelial cells through catalase-mediated suppression of excessive reactive oxygen species.

Authors:  Qiong Wang; Wenshu Chen; Xiuling Xu; Bilan Li; Weiyang He; Mabel T Padilla; Jun-Ho Jang; Toru Nyunoya; Shantu Amin; Xia Wang; Yong Lin
Journal:  Carcinogenesis       Date:  2013-04-30       Impact factor: 4.944

7.  Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis.

Authors:  Liping Ma; Hongjun Peng; Kunsheng Li; Runrun Zhao; Li Li; Yilong Yu; Xiaoming Wang; Zhifeng Han
Journal:  Mol Med Rep       Date:  2015-06-18       Impact factor: 2.952

8.  Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition.

Authors:  Qiong Wang; Shaoqing Shi; Weiyang He; Mabel T Padilla; Lin Zhang; Xia Wang; Bin Zhang; Yong Lin
Journal:  Oncotarget       Date:  2014-03-15

Review 9.  Understanding Lung Carcinogenesis from a Morphostatic Perspective: Prevention and Therapeutic Potential of Phytochemicals for Targeting Cancer Stem Cells.

Authors:  Win Sen Heng; Frank A E Kruyt; Shiau-Chuen Cheah
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

10.  Induction of apoptosis by luteolin involving akt inactivation in human 786-o renal cell carcinoma cells.

Authors:  Yen-Chuan Ou; Yu-Hsiang Kuan; Jian-Ri Li; Shue-Ling Raung; Chung-Chiang Wang; Yu-Yeh Hung; Chun-Jung Chen
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-05       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.